Quirk Shae E, Koivumaa-Honkanen Heli, Stuart Amanda L, Mohebbi Mohammadreza, Honkanen Risto J, Heikkinen Jeremi, Berk Michael, Pasco Julie A, Williams Lana J
Deakin University, Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong, Victoria, Australia
Institute of Clinical Medicine, Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Kuopio, Finland.
BMJ Open. 2025 Mar 15;15(3):e084797. doi: 10.1136/bmjopen-2024-084797.
There is developing evidence of excess mortality among people with mental disorders. This protocol presents the methodology to undertake a systematic review to definitively examine the current evidence on the risk of all-cause and cause-specific mortality in people with mental disorders (mood, anxiety, substance use, eating, personality and psychotic disorders) compared with populations without mental disorders in broadly representative studies of general populations worldwide. In addition, we seek to understand whether the excess mortality has increased further over time, and if the COVID-19 pandemic exacerbated the excess mortality in people with mental disorders.
A systematic review of cohort studies will be conducted. The search strategy to yield peer-reviewed (in Medline Complete, CINAHL Complete, Embase and APA PsycInfo) and published grey literature will be developed in consultation with a liaison librarian. A preliminary scope of peer-reviewed literature in Medline Complete using the EBSCOhost platform was conducted on 20 November 2023. Epidemiological cohort or case-control studies will be eligible if they examine (1) diagnoses of mental disorders (according to the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases classification systems) and (2) risk of all-cause and/or cause-specific mortality. A critical appraisal of the included studies will be undertaken. A synthesis of the findings will include the characteristics of the included studies, critical appraisal and a summary of the key findings in texts and visually in tables. Where appropriate, meta-analyses and subgroup analyses will be performed.
This study is exempt from ethics approval, as it does not include identifiable human data. The outcomes of the proposed review will be shared in national/international conferences, published in a peer-reviewed journal and disseminated to new and existing networks.
CRD42023477494.
越来越多的证据表明,精神障碍患者的死亡率过高。本方案介绍了进行系统评价的方法,以明确审查当前关于精神障碍(情绪、焦虑、物质使用、饮食、人格和精神分裂症)患者与全球普通人群中无精神障碍人群相比的全因死亡率和特定病因死亡率风险的证据。此外,我们试图了解随着时间的推移,过高死亡率是否进一步增加,以及新冠疫情是否加剧了精神障碍患者的过高死亡率。
将对队列研究进行系统评价。将与联络图书馆员协商制定检索策略,以获取同行评审文献(在Medline Complete、CINAHL Complete、Embase和APA PsycInfo中)和已发表的灰色文献。2023年11月20日在EBSCOhost平台上对Medline Complete中的同行评审文献进行了初步检索。如果流行病学队列研究或病例对照研究考察(1)精神障碍诊断(根据《精神障碍诊断与统计手册》和《国际疾病分类》分类系统)和(2)全因和/或特定病因死亡率风险,则符合纳入标准。将对纳入研究进行严格评价。研究结果的综合将包括纳入研究的特征、严格评价以及文本和表格形式的关键结果总结。在适当情况下,将进行荟萃分析和亚组分析。
本研究无需伦理批准,因为它不包括可识别的人类数据。拟议综述的结果将在国家/国际会议上分享,发表在同行评审期刊上,并传播给新的和现有的网络。
PROSPERO注册号:CRD42023477494